Premium
LONG‐ACTING THYROID STIMULATOR (LATS) AND LONG ACTING THYROID STIMULATOR PROTECTOR (LATS‐P) IN UNTREATED THYROTOXICOSIS
Author(s) -
HARDISTY C. A.,
HANFORD LINDA,
HUMPHRIES HAZEL,
MUNRO D. S.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb02975.x
Subject(s) - medicine , endocrinology , thyroid , graves' disease
SUMMARY The prevalance of serum LATS and LATS‐P in untreated Graves' disease has been studied in eighty‐three patients with thyroid overactivity; twelve (14%) were found to have significant levels of LATS and LATS‐P whilst fifty‐nine (72%) had significant levels of LATS‐P alone. Twelve (14%) had neither activity. There was a very wide range in both activities. LATS was invariably found in association with a significantly greater concentration of LATS‐P. There was no correlation between LATS‐P and thyroid mass, as estimated from scintiscanning, thyroidal radioiodine uptake at 4 and 48 h, total serum T4 and total serum T3. Neither LATS nor LATS‐P were detected in eleven patients with toxic multinodular goitre nor four with solitary toxic adenoma.